Red fluorescent protein

Slingshot Biosciences Unveils Revolutionary Fluorescent Protein Control Series to Enhance Flow Cytometry Analysis

Retrieved on: 
Monday, July 10, 2023
Health, Genetics, General Health, Research, Science, Biotechnology, Mouse, Red fluorescent protein, Canadian Aviation Regulations, Benchmarking, MCherry, Collection, Vaccine

a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraCompⓇ fluorescent protein series collection.

Key Points: 
  • a leading provider of cell mimic control products, is proud to announce the launch of its new SpectraCompⓇ fluorescent protein series collection.
  • This groundbreaking series provides scientists with a cutting-edge fluorescent protein control platform for use in flow cytometry analysis.
  • Slingshot’s new SpectraCompⓇ series collection of cutting-edge fluorescent proteins: SpectraCompⓇ eGFP and SpectraCompⓇ mCherry, exceptional controls for unmixing, compensation, and benchmarking for flow cytometry analysis.
  • “We are thrilled to bring this revolutionary technology to the scientific community,” says Dr. Jeffrey Kim, CEO of Slingshot Biosciences.

groundcover Raises $24.5M For The Next Generation Of APM With eBPF

Retrieved on: 
Wednesday, September 14, 2022
Giant, DevOps, NYSE, APM, TEL, Entrepreneurship, Firewall (computing), VCS, Lemonade, CEO, Technology, Red fluorescent protein, Solution, Kubernetes, Attitude, Business, Budget, Video game, Management, Apple, Linux

The result is clear: over 70% of teams do not have an APM tier in place (DevOps Pulse 2022).

Key Points: 
  • The result is clear: over 70% of teams do not have an APM tier in place (DevOps Pulse 2022).
  • By using eBPF to collect observability data straight from the Linux kernel, groundcover requires no R&D efforts in the process.
  • "The APM space is thirsty for innovation and I am psyched to be introducing eBPF into this space.
  • "groundcover is addressing a gap in the market with the powerful innovation of the APM sphere," said Oren Zeev of Zeev Ventures.

Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver

Retrieved on: 
Tuesday, July 5, 2022
Cell, PKU, Red fluorescent protein, Patient, Heart, ALT, Liver, PNH, Periphery, Tissue, GLOBE, Re Recher's Will Trusts, Single, Method, COVID-19, VGS, AAV, CNS, Hunter syndrome, Central nervous system, Company, Failure, Variation, Disease, Beckman Center for Molecular and Genetic Medicine, U.S. Securities and Exchange Commission, Tropism, Galactose, MLD, Organic acid, Phenylketonuria, Paroxysmal nocturnal hemoglobinuria, Therapy, AST, Alanine transaminase, Private Securities Litigation Reform Act, Gene editing, Antibody, Nasdaq, SEC, Family, Safety, Manuscript, Security (finance), Vaccine, Dietary supplement, Medical imaging, Gum arabic, Pharmaceutical industry, Brain

BEDFORD, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of data showing that AAVHSC16, one of the capsids in its family of 15 naturally occurring AAVHSCs, demonstrated low levels of tropism to the liver while maintaining robust distribution to the central nervous system (CNS) and peripheral organs following a single I.V. administration in preclinical models. The Company believes that its unique properties, with high levels of tropism to the brain, heart and muscle, and no elevations in liver enzymes, could make AAVHSC16 an attractive capsid for new disease indications with Homology’s genetic medicines platform.

Key Points: 
  • Homologys AAVHSC capsids differ from each other by one to four amino acids, resulting in differences in biodistribution and transduction efficiencies.
  • As described in the manuscript, AAVHSC16 has two unique amino acids, 501I and 706C, in addition to 505R that is shared across six AAVHSC serotypes.
  • The combination of the unique naturally occurring amino acids at positions 501I and 505R in AAVHSC16 were shown to contribute to reduced galactose-binding.
  • AAVHSC16 Has Significantly Reduced Liver Transduction in In Vivo and In Vitro Models, with High Tropism to other Tissues Following a Single I.V.

Secure Open Source 5G Gains Momentum as Community Focuses on Re-aggregation, with 5G Super-Blueprints and New Members

Retrieved on: 
Tuesday, April 12, 2022
Cloud, RAN, Node.js, Housing, Regal, LTE, Linux Foundation, Foundation, Adoption, Executive Orders, OEM, Telco, Automation, MEC, Silver, Outline, ATOS, LFN, Linux, Organization, ONAP, EMCO, Open Networking Foundation, Enterprise, Denial-of-service attack, Technology, Keysight, Red fluorescent protein, Digital transformation, Ecosystem, Solution, Walmart, White House, Firewall (computing), Bill of materials, Digital, IOT, Open Source Security Foundation, Industry, Container, Network equipment, Renewable energy, Risk management, Magma, Telecom, Atos

The 5G Super Blueprint is now integrated across even more projectsincluding Magma (1.6), EMCO, and Anuketbuilding open source components applicable to a variety of industry use cases.

Key Points: 
  • The 5G Super Blueprint is now integrated across even more projectsincluding Magma (1.6), EMCO, and Anuketbuilding open source components applicable to a variety of industry use cases.
  • Preliminary scoping for future integrations with the O-RAN Software Community have begun, setting the stage for end-to-end open source interoperability from the core through the RAN and future compliance activities.
  • Telaverge's open source based private LTE and 5G cores are pre-integrated with Regal for zero touch testing and deployment.
  • Founded in 2000, the Linux Foundation is supported by more than 2,000 members and is the world's leading home for collaboration on open source software, open standards, open data, and open hardware.